Prilosec OTC Patent Extension Submission Pending At PTO
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity